

CITATION REPORT

List of articles citing

Hepatitis B surface antigen seroclearance during chronic HBV infection

DOI: 10.3851/imp1497
Antiviral Therapy, 2010, 15, 133-43.

Source: <https://exaly.com/paper-pdf/47650319/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
147	Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 2727-34	4	73
146	Does chemotherapy prevent HBV-related hepatocellular carcinoma? <i>Pros.</i> 2010 , 42 Suppl 3, S293-7		5
145	Development of hepatocellular carcinoma after seroclearance of hepatitis surface antigen. <i>Acta Hepatologica Japonica</i> , 2011 , 52, 176-183	0.3	
144	Review article: current antiviral therapy of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 1145-58	6.1	66
143	Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. <i>Liver International</i> , 2011 , 31 Suppl 1, 122-8	7.9	27
142	Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. <i>Hepatology</i> , 2011 , 53, 2121-9	11.2	67
141	Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. <i>Hepatology</i> , 2011 , 54, E1-9	11.2	52
140	Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. 2011 , 18, 1943-50		32
139	Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. 2012 , 28, 156-64		17
138	Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. 2012 , 54, 88-90		18
137	HBsAg Quantification in Clinical Practice. 2012 , 2, 75-80		4
136	Clinical Implications of the Innate and Adaptive Immune Response to HBV and HCV. 2012 , 11, 243-249		
135	Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 297-302	6.9	57
134	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. 2012 , 6, 531-61		768
133	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. <i>Hepatology</i> , 2012 , 55, 68-76	11.2	104
132	The Role of HBsAg Quantification in the Natural Course of HBV Infection in Asia. 2013 , 12, 174-180		
131	Evolution of viral biomarkers in predicting outcomes of chronic hepatitis B patients: From DNA to surface antigen. 2013 , 25, 75-81		2

130	Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. <i>Digestive Diseases and Sciences</i> , 2013 , 58, 275-81	4	31
129	Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. 2013 , 48, 13-21		84
128	Impact of therapy on the long-term outcome of chronic hepatitis B. 2013 , 17, 413-23		34
127	A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. <i>Journal of Hepatology</i> , 2013 , 58, 853-60	13.4	71
126	Impact of therapy on the outcome of chronic hepatitis B. <i>Liver International</i> , 2013 , 33 Suppl 1, 111-5	7.9	49
125	The correlation between T helper type 17 cells and clinical characters in Chinese paediatric patients with chronic hepatitis B. 2013 , 171, 307-12		6
124	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir. <i>Antiviral Therapy</i> , 2013 , 18, 691-8	1.6	15
123	Natural History of Chronic Hepatitis B Virus Infection. 2013 , 143-153		2
122	Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. 2013 , 8, e53008		39
121	[Clinical significance of hepatitis B surface antigen quantification in chronic hepatitis B]. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2014 , 63, 335-40	0.6	
120	Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. 2014 , 63, 1648-57		129
119	Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. 2014 , 3, e64		84
118	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , 2014 , 34, e71-9	7.9	11
117	Loss of HBsAg and antiviral treatment: from basics to clinical significance. 2014 , 8, 39-54		6
116	A rapid and sensitive method based on magnetic beads for the detection of hepatitis B virus surface antigen in human serum. 2014 , 29, 591-7		9
115	Clinical implications of hepatitis B surface antigen quantitation in the natural history of chronic hepatitis B virus infection. 2014 , 59, 228-34		6
114	New therapeutic perspectives in HBV: when to stop NAs. <i>Liver International</i> , 2014 , 34 Suppl 1, 146-53	7.9	18
113	Factors affecting the natural decay of hepatitis B surface antigen in children with chronic hepatitis B virus infection during long-term follow-up. 2014 , 165, 767-72.e1		23

112	Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience. 2015 , 7, 101-7		4
111	Hepatitis B prevalence and incidence in Greenland: a population-based cohort study. 2015 , 181, 422-30		24
110	Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System. 2015 , 211, 1566-73		13
109	Effect of serum hepatitis B surface antigen levels on predicting the clinical outcomes of chronic hepatitis B infection: A meta-analysis. 2015 , 45, 1004-1013		13
108	What can we learn from hepatitis B virus clinical cohorts?. <i>Liver International</i> , 2015 , 35 Suppl 1, 91-9	7.9	10
107	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. 2015 , 9, 35-42		11
106	Downregulation of immunosuppressive environment in patients with chronic HBV hepatitis on maintained remission. 2015 , 6, 52		2
105	Molecular mechanisms underlying HBsAg negativity in occult HBV infection. 2015 , 34, 1709-31		19
104	Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. <i>Journal of Hepatology</i> , 2015 , 62, 1092-9	13.4	82
103	Low serum hyaluronic acid levels associated with spontaneous HBsAg clearance. 2015 , 34, 2183-9		2
102	Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection. <i>Liver International</i> , 2015 , 35, 130-9	7.9	25
101	The effects of cytokines on spontaneous hepatitis B surface antigen seroconversion in chronic hepatitis B virus infection. 2015 , 194, 690-6		15
100	Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1311-8	6.1	27
99	Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1253-61	6.1	47
98	Molecular Detection and Characterization of Hepatitis B Virus. 2016 , 449-464		
97	HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy. 2016 , 10, 727-9		10
96	Letter: clinical outcomes of HBsAg loss in chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 535-6	6.1	2
95	HBsAg spontaneous seroclearance in a cohort of HBeAg-seronegative patients with chronic hepatitis B virus infection. 2016 , 88, 79-85		18

94	Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 210-1	6.1	1
93	Letter: clinical outcomes of HBsAg loss in chronic HBV infection - author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 536-7	6.1	
92	Hepatitis B viremia in completely immunized individuals negative for anti-hepatitis B core antibody. 2016 , 95, e5625		5
91	Revisiting the Natural History of Chronic HBV Infection. 2016 , 15, 141-149		11
90	Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area. <i>Liver International</i> , 2016 , 36, 1351-61	7.9	15
89	Natural History of Hepatitis B Virus Infection. 2016 , 217-247		3
88	Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: the differential serological diagnosis. 2016 , 35, 29-40		13
87	Chronic hepatitis B surface antigen seroclearance-related immune factors. 2017 , 47, 49-59		9
86	Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors. 2017 , 17, 9		1
85	HBsAg may reappear following reactivation in individuals with spontaneous HBsAg seroclearance 8 years previously. 2017 , 145, 728-738		7
84	Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment. 2017 , 249, 189-193		7
83	Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. 2017 , 96, e6554		12
82	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2017 , 67, 902-908	13.4	84
81	Estimating age-related incidence of HBsAg seroclearance in chronic hepatitis B virus infections of China by using a dynamic compartmental model. <i>Scientific Reports</i> , 2017 , 7, 2912	4.9	8
80	Drugs in Development for Hepatitis B. 2017 , 77, 1263-1280		21
79	Treatment outcomes in treatment experienced and treatment naïve patients on Tenofovir disoproxil fumarate for chronic hepatitis B. 2017 , 74, 100-102		
78	The current status and future directions of hepatitis B antiviral drug discovery. 2017 , 12, 5-15		35
77	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). <i>Journal of Clinical and Translational Hepatology</i> , 2017 , 5, 297-318	5.2	136

76	Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment. 2017 , 130, 559-565		10
75	HBV DNA Integration: Molecular Mechanisms and Clinical Implications. <i>Viruses</i> , 2017 , 9,	6.2	175
74	Spontaneous Hepatitis B Seroclearance upon Development of Hepatocellular Carcinoma. 2017 , 11, 797-802		
73	Estimating the impact of test-and-treat strategies on hepatitis B virus infection in China by using an age-structured mathematical model. 2018 , 97, e0484		6
72	Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women. 2018 , 263-296		
71	Chronic Hepatitis B Infection: A Review. 2018 , 319, 1802-1813		266
70	Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients. <i>Liver International</i> , 2018 , 38, 38-49	7.9	15
69	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2017 ,	13.4	47
68	Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy. <i>Liver International</i> , 2018 , 38, 627-635	7.9	2
67	Pregnancy in a patient with portal hypertension secondary to liver cirrhosis. 2018 , 2018,		3
66	A single-center, single-blind study to evaluate the clinical sensitivity, specificity, and agreement between Elecsys Anti-HBc II and Elecsys Anti-HBc in a Korean population. 2018 , 109, 41-44		0
65	Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B. 2018 , 13, e0199094		2
64	HBV infection and extra-hepatic cancers in adolescents and 20s: A retrospective study in China. 2018 , 55, 149-155		11
63	Systematic review and meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1172-1179	3.4	6
62	Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. 2018 , 6, e659-e667		24
61	Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. <i>Journal of Viral Hepatitis</i> , 2019 , 26 Suppl 1, 32-41	3.4	9
60	Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	0
59	Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. 2019 , 4, 227-238		37

58	Using Machine Learning Algorithms to Predict Hepatitis B Surface Antigen Seroclearance. 2019 , 2019, 6915850		14
57	A retrospective serological survey of hepatitis B virus infection in Northeast China. 2019 , 19, 440		7
56	Perinatal immunoprophylaxis in babies born to hepatitis B virus-positive mothers in Queensland Australia: A data linkage study. 2019 , 37, 2884-2888		1
55	Affinity binding of aptamers to agarose with DNA tetrahedron for removal of hepatitis B virus surface antigen. 2019 , 178, 80-86		9
54	Single-nucleotide polymorphism of rs7944135 (macrophage-expressed gene 1) is associated with hepatitis B surface antigen seroclearance in chronic hepatitis B infection: A cohort study. 2019 , 98, e17936		
53	Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review. 2019 , 53, 294-310		4
52	REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection. 2019 , 5, 675-687		38
51	Immunological cure of HBV infection. 2019 , 13, 113-124		20
50	Novel developments of hepatitis B: treatment goals, agents and monitoring tools. 2019 , 12, 109-120		20
49	The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. <i>Liver International</i> , 2020 , 40, 549-557	7.9	6
48	Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 526-536	3.4	4
47	Challenges and opportunities for hepatitis B cure in the setting of HIV--hepatitis B virus co-infection. <i>Current Opinion in HIV and AIDS</i> , 2020 , 15, 193-199	4.2	2
46	Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance. <i>JGH Open</i> , 2020 , 4, 698-706	1.8	3
45	Hepatitis B Surface Antigen Levels Are Related to Spontaneous Hepatitis B Surface Antigen Seroconversion in Inactive Hepatitis B Carriers. <i>Journal of Clinical Gastroenterology</i> , 2020 , 54, 573-576		3
44	Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance. <i>Hepatology</i> , 2021 , 73, 2155-2166	11.2	9
43	Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection. <i>BioMed Research International</i> , 2020 , 2020, 6820179	3	1
42	Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. <i>Vaccines</i> , 2020 , 8,	5.3	8
41	Will we need novel combinations to cure HBV infection?. <i>Liver International</i> , 2020 , 40 Suppl 1, 35-42	7.9	5

40	Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. <i>Journal of Hepatology</i> , 2020 , 73, 409-422	13.4	39
39	Spontaneous Flares of Chronic Hepatitis B Virus in Hepatitis Be Antigen Negative Carriers Who Subsequently Clear Hepatitis B Surface Antigen. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 257-262	4	
38	Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection. <i>Scientific Reports</i> , 2021 , 11, 200	4.9	3
37	B Cell-mediated Humoral Immunity in Chronic Hepatitis B Infection. <i>Journal of Clinical and Translational Hepatology</i> , 2021 , 9, 592-597	5.2	0
36	Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	0
35	Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021 , 77, 285-293	0.6	1
34	Microfluidic Paper-Based Analytical Devices: From Design to Applications. <i>Chemical Reviews</i> , 2021 , 121, 11835-11885	68.1	42
33	Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	0
32	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 3239-3246	4	
31	No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1545-1553	3.4	0
30	Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients. <i>International Journal of Clinical Practice</i> , 2021 , e14899	2.9	0
29	Guidelines for Prevention and Treatment of Chronic Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2021 , 9, 769-791	5.2	5
28	Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti-HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure. <i>Microbiology and Immunology</i> , 2021 ,	2.7	1
27	Nanomedicine as a promising strategy for the theranostics of infectious diseases. <i>Journal of Materials Chemistry B</i> , 2021 , 9, 7878-7908	7.3	3
26	Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women. 2021 , 375-410		
25	Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 1089-1097	3.4	11
24	Then and now: the progress in hepatitis B treatment over the past 20 years. <i>World Journal of Gastroenterology</i> , 2014 , 20, 401-13	5.6	40
23	Impact of IL28B and gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. <i>World Journal of Gastroenterology</i> , 2016 , 22, 9186-9195	5.6	10

22	A case of chronic hepatitis B which achieved hepatitis B surface antigen seroclearance during combination therapy with peginterferon alfa-2b and entecavir. <i>Acta Hepatologica Japonica</i> , 2012 , 53, 42-47	0.3	
21	Comparison of each HBs antigen assay and its clinical utility. <i>Acta Hepatologica Japonica</i> , 2014 , 55, 310-324	0.3	3
20	A case of HBsAg seroclearance by readministration of lamivudine and adefovir dipivoxil in patient with liver cirrhosis due to hepatitis B virus infection. <i>Acta Hepatologica Japonica</i> , 2014 , 55, 706-712	0.3	
19	A study on validity of measurement of nitrate nitrogen in soil water by portable ion meter. <i>Journal of the Japanese Society of Revegetation Technology</i> , 2018 , 44, 131-134	0.1	
18	Understanding the antiviral effects of RNAi-based therapy on chronic hepatitis B infection.		
17	Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors. <i>Annals of Gastroenterology</i> , 2015 , 28, 173-181	2.2	15
16	Clinical implications of serum hepatitis B virus RNA quantitation in untreated chronic hepatitis B virus-infected patients. <i>International Journal of Clinical and Experimental Pathology</i> , 2021 , 14, 140-149	1.4	
15	How to interpret viral markers in the management of chronic hepatitis B infection. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	
14	Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 ,	6.1	2
13	Viral hepatitis: Innovations and expectations.. <i>World Journal of Gastroenterology</i> , 2022 , 28, 517-531	5.6	1
12	Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.. <i>Virologica Sinica</i> , 2022 ,	6.4	1
11	Seroclearance of HBsAg in Chronic Hepatitis B Patients after a Tolerance-Breaking Therapy: GM-CSF, followed by Human HBV Vaccine.		
10	HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.. <i>Viruses</i> , 2022 , 14,	6.2	1
9	Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study. <i>PLOS Global Public Health</i> , 2022 , 2, e0000394		0
8	Serum HBcrAg and hepatocellular carcinoma in a Taiwanese population seronegative for HBsAg and anti-HCV. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	
7	Rigorous hepatitis B surface antigen analyses and identification of hepatitis B chronicity amongst South Africans attending public health facilities over a five-year period: 2015 to 2019.		
6	HBV genotype-dependent association of HLA Variants with the Serodecline of HBsAg in Chronic Hepatitis B Patients: a 14-year Follow-up Study.		0
5	Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-β treatment and retreatment. 28, 5784-5800		0

- 4 Interferon and interferon-stimulated genes in HBV treatment. 13, 1
- 3 HBV genotype-dependent association of HLA variants with the serodecline of HBsAg in chronic hepatitis B patients. **2023**, 13, 0
- 2 Comparison of HBV-DNA Levels with Biochemical and Microbiological Parameters for Chronic Hepatitis Evaluation, Bursa, Turkey. **2021**, 9, 17-24 0
- 1 Remote and short-term prediction of spontaneous HBsAg seroclearance. **2023**, 0